Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy - Scott, S A; Sangkuhl, K; Gardner, E E; Stein, C M; Hulot, J-S; Johnson, J A; Roden, D M; Klein, T E; Shuldiner, A R (Clinical pharmacology and therapeutics, 2011)
Keywords: Acute Coronary Syndrome - therapy; Alleles; Angioplasty, Balloon, Coronary - methods; Aryl Hydrocarbon Hydroxylases - genetics; Aryl Hydrocarbon Hydroxylases - metabolism; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Pharmacogenetics - methods; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - metabolism; Platelet Aggregation Inhibitors - therapeutic use; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Ticlopidine - metabolism; Ticlopidine - therapeutic use